What do oncologists think of the CABINET trial (CABOMETYX®)?
CABINET — Previously treated, advanced pancreatic and extra-pancreatic neuroendocrine tumors (pNET/epNET)
FDA APPROVED · Mar 2025FDA-approved March 26, 2025, for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors.
Physician voices — verbatim
Full physician voice list (4)
What do oncologists think of the CheckMate-9ER trial (CABOMETYX®)?
CheckMate-9ER — First-line advanced renal cell carcinoma (nivolumab + cabozantinib)
FDA APPROVED · Jan 2021FDA-approved January 22, 2021, for cabozantinib in combination with nivolumab for the first-line treatment of advanced renal cell carcinoma.
Physician voices — verbatim
Full physician voice list (24)
What do oncologists think of the COSMIC-313 trial (CABOMETYX®)?
COSMIC-313 — First-line intermediate/poor-risk advanced RCC (cabozantinib + nivolumab + ipilimumab triplet) — INVESTIGATIONAL
INVESTIGATIONALInvestigational. COSMIC-313 tested a cabozantinib + nivolumab + ipilimumab triplet against nivolumab + ipilimumab in first-line intermediate/poor-risk advanced RCC; it improved progression-free survival but the triplet regimen is not FDA-approved.
Physician voices — verbatim
Full physician voice list (10)
Full conference coverage and trial data: KOL Pulse trial profile coming soon.
What do oncologists think of the CONTACT-02 trial (CABOMETYX®)?
CONTACT-02 — Metastatic castration-resistant prostate cancer with measurable soft-tissue disease after a prior novel hormonal therapy (cabozantinib + atezolizumab) — INVESTIGATIONAL
INVESTIGATIONAL · OS NOT METInvestigational. CONTACT-02 tested cabozantinib + atezolizumab against a second novel hormonal therapy in metastatic castration-resistant prostate cancer; it met its progression-free-survival co-primary endpoint but did not achieve a statistically significant overall-survival benefit. Cabozantinib is not FDA-approved for prostate cancer.
Physician voices — verbatim
Full physician voice list (48)
Full conference coverage and trial data: KOL Pulse trial profile coming soon.
CABOMETYX® — FDA status
FDA APPROVEDCABOMETYX® (cabozantinib) is FDA-approved across multiple advanced cancers — including advanced renal cell carcinoma (alone and, first-line, with nivolumab), previously treated hepatocellular carcinoma, and previously treated advanced pancreatic and extra-pancreatic neuroendocrine tumors. For the full, current list of FDA indications and prescribing information, see cabometyx.com or FDA label (DailyMed). KOL Pulse indexes the physician conversation; the label is owned and maintained by the manufacturer.
CABOMETYX® sentiment — FAQ
CABINET
What do oncologists think of the CABINET trial (CABOMETYX®)?
Across 4 verified physician voices in KOL Pulse's index for CABINET, 0% expressed positive sentiment, 0% were nuanced (praising the result while flagging a caveat), 100% were neutral, and 0% were critical. Positive voices highlight extending an oral TKI into previously treated advanced neuroendocrine tumors, a setting with few options, with a clear progression-free-survival benefit; nuanced and critical voices flag toxicity and dose management in a chronically treated NET population, and sequencing versus everolimus and lutetium Lu 177 dotatate.
Where can I find the CABINET trial data for CABOMETYX® (cabozantinib)?
CABINET is registered as NCT03375320 and studied CABOMETYX® (cabozantinib) in Previously treated, advanced pancreatic and extra-pancreatic neuroendocrine tumors (pNET/epNET). For the full CABINET trial data and conference coverage, see the KOL Pulse CABINET trial profile at kolpulse.com/kol-pulse-trial-profile-cabinet.
CheckMate-9ER
What do oncologists think of the CheckMate-9ER trial (CABOMETYX®)?
Across 24 verified physician voices in KOL Pulse's index for CheckMate-9ER, 33% expressed positive sentiment, 4% were nuanced (praising the result while flagging a caveat), 63% were neutral, and 0% were critical. Positive voices highlight the progression-free and overall-survival benefit of the cabozantinib + nivolumab IO/TKI doublet as a first-line RCC standard of care; nuanced and critical voices flag how it sequences and compares against other IO/TKI and IO/IO first-line regimens, and the tolerability of the doublet.
Where can I find the CheckMate-9ER trial data for CABOMETYX® (cabozantinib)?
CheckMate-9ER is registered as NCT03141177 and studied CABOMETYX® (cabozantinib) in First-line advanced renal cell carcinoma (nivolumab + cabozantinib). For the full CheckMate-9ER trial data and conference coverage, see the KOL Pulse CheckMate-9ER trial profile at kolpulse.com/kol-pulse-trial-profile-checkmate-9er-1.
COSMIC-313
What do oncologists think of the COSMIC-313 trial (CABOMETYX®)?
Across 10 verified physician voices in KOL Pulse's index for COSMIC-313, 10% expressed positive sentiment, 30% were nuanced (praising the result while flagging a caveat), 60% were neutral, and 0% were critical. Positive voices highlight the progression-free-survival benefit of intensifying first-line therapy with a cabozantinib + dual-checkpoint triplet in higher-risk RCC; nuanced and critical voices flag the added toxicity and treatment-discontinuation burden of the triplet, immature overall survival, and whether the PFS gain justifies escalation.
Where can I find the COSMIC-313 trial data for CABOMETYX® (cabozantinib)?
COSMIC-313 is registered as NCT03937219 and studied CABOMETYX® (cabozantinib) in First-line intermediate/poor-risk advanced RCC (cabozantinib + nivolumab + ipilimumab triplet) — INVESTIGATIONAL. KOL Pulse's COSMIC-313 trial profile is coming soon.
CONTACT-02
What do oncologists think of the CONTACT-02 trial (CABOMETYX®)?
Across 48 verified physician voices in KOL Pulse's index for CONTACT-02, 27% expressed positive sentiment, 25% were nuanced (praising the result while flagging a caveat), 25% were neutral, and 23% were critical. Positive voices highlight a non-androgen-receptor-targeted option delivering a progression-free-survival benefit in a difficult, previously treated mCRPC population; nuanced and critical voices flag the lack of a statistically significant overall-survival benefit at final analysis and the higher adverse-event burden of the combination.
Where can I find the CONTACT-02 trial data for CABOMETYX® (cabozantinib)?
CONTACT-02 is registered as NCT04446117 and studied CABOMETYX® (cabozantinib) in Metastatic castration-resistant prostate cancer with measurable soft-tissue disease after a prior novel hormonal therapy (cabozantinib + atezolizumab) — INVESTIGATIONAL. KOL Pulse's CONTACT-02 trial profile is coming soon.
Regulatory
Is CABOMETYX® (cabozantinib) FDA approved?
CABOMETYX® is FDA-approved. KOL Pulse organizes this page by clinical trial and links out to the manufacturer's brand site and the FDA label for the full, current list of FDA indications and prescribing information — the label is owned and updated by the manufacturer, so we point to it rather than reproducing it.